Showing results (51-60 of 160) with videos related to

Sort By:
Pageof 16
Brain Imaging and Behavior|September 22, 2018
Cerebral white matter Hyperintensities in HIV-positive patientsAlice Trentalange, Adolfo Prochet, Daniele Imperiale, et al.
International Journal of Antimicrobial Agents|April 4, 2015
Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogeneticsJessica Cusato, Sarah Allegra, Amedeo De Nicolò, et al.
AIDS (London, England)|May 5, 2012
Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogeneticsAndrea Calcagno, Aylin Yilmaz, Jessica Cusato, et al.
International Journal of Pharmaceutics|December 9, 2015
Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic studyGiovanna Fatiguso, Sarah Allegra, Andrea Calcagno, et al.
The Journal of Antimicrobial Chemotherapy|July 6, 2014
Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphismsAntonio D'Avolio, Chiara Carcieri, Jessica Cusato, et al.
Pharmacogenomics|June 9, 2017
Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokineticsSarah Allegra, Giovanna Fatiguso, Andrea Calcagno, et al.
International Journal of Antimicrobial Agents|January 18, 2016
Efavirenz pharmacogenetics in a cohort of Italian patientsJessica Cusato, Cristina Tomasello, Marco Simiele, et al.
Diagnostics (Basel, Switzerland)|June 2, 2021
Blood-Brain Barrier Impairment in Patients Living with HIV: Predictors and Associated BiomarkersGiulia Caligaris, Mattia Trunfio, Valeria Ghisetti, et al.
British Journal of Clinical Pharmacology|June 12, 2012
Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devicesAndrea Calcagno, Antonio D'Avolio, Marco Simiele, et al.
The Journal of Steroid Biochemistry and Molecular Biology|February 25, 2021
Trend of 25-hydroxycholesterol and 27-hydroxycholesterol plasma levels in patients affected by active chronic hepatitis B virus infection and inactive carriersLucio Boglione, Claudio Caccia, Andrea Civra, et al.
Pageof 16